Gastroenterology · 2026
Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Gi-Ae, Jang Heejoon, Kim Moon Young, Park Jeong Hwan, Park Jung Gil, Cho Eun-Young, Jeong Jae Yoon, Jeong Seogsong, Han Seul Ki, Kwon Heesu, Jung Youngae, Hwang Geum-Sook, Lee Yu Rim, Park Soo Young, Kim Sang Gyune, Kim Won
Аннотация
BACKGROUND & AIMS: Clinical outcomes and histologic characteristics of biopsy-proven steatotic liver disease (SLD) subtypes remain understudied. We investigated clinical outcomes and fibrosis patterns in metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related liver disease (MetALD), and alcohol-associated liver disease (ALD).
METHODS: This multicenter prospective cohort study enrolled 2551 individuals with biopsy-proven SLD or non-SLD controls between 2010 and 2023. Risks of all-cause mortality, liver-related events (LREs), cardiovascular disease, and extrahepatic malignancies were assessed using Fine-Gray models. Artificial intelligence (AI)-based quantitative fibrosis analysis using second harmonic generation imaging was performed on 88 liver biopsies (28 MASLD, 30 MetALD, and 30 ALD) to assess zone-specific collagen distribution patterns.
RESULTS: During a median follow-up of 43.8 months, 166 deaths and 162 LREs occurred. Compared with non-SLD, MetALD (adjusted subdistribution hazard ratio [ASHR], 3.05; 95% confidence interval [CI], 1.08-8.58) and ALD (ASHR, 5.80; 95% CI, 2.26-14.87) demonstrated substantially increased all-cause mortality risk. MetALD (ASHR, 6.13; 95% CI, 1.33-28.20) and ALD (ASHR, 10.96; 95% CI, 2.55-47.14) also exhibited elevated LRE risk. In the advanced fibrosis (≥F3) subgroup, ALD demonstrated higher mortality and LRE risks than MASLD. AI-based analysis revealed that MetALD and ALD exhibited significantly higher collagen density in periportal and zone 2 regions compared with MASLD, despite comparable conventional fibrosis stages.
CONCLUSIONS: MetALD and ALD are independently associated with substantially increased all-cause mortality and LRE risks compared with non-SLD. Distinct zone-specific collagen patterns identified by AI analysis suggest unique fibrotic progression pathways in MetALD and ALD, supporting the need for tailored risk stratification and targeted management strategies.
METHODS: This multicenter prospective cohort study enrolled 2551 individuals with biopsy-proven SLD or non-SLD controls between 2010 and 2023. Risks of all-cause mortality, liver-related events (LREs), cardiovascular disease, and extrahepatic malignancies were assessed using Fine-Gray models. Artificial intelligence (AI)-based quantitative fibrosis analysis using second harmonic generation imaging was performed on 88 liver biopsies (28 MASLD, 30 MetALD, and 30 ALD) to assess zone-specific collagen distribution patterns.
RESULTS: During a median follow-up of 43.8 months, 166 deaths and 162 LREs occurred. Compared with non-SLD, MetALD (adjusted subdistribution hazard ratio [ASHR], 3.05; 95% confidence interval [CI], 1.08-8.58) and ALD (ASHR, 5.80; 95% CI, 2.26-14.87) demonstrated substantially increased all-cause mortality risk. MetALD (ASHR, 6.13; 95% CI, 1.33-28.20) and ALD (ASHR, 10.96; 95% CI, 2.55-47.14) also exhibited elevated LRE risk. In the advanced fibrosis (≥F3) subgroup, ALD demonstrated higher mortality and LRE risks than MASLD. AI-based analysis revealed that MetALD and ALD exhibited significantly higher collagen density in periportal and zone 2 regions compared with MASLD, despite comparable conventional fibrosis stages.
CONCLUSIONS: MetALD and ALD are independently associated with substantially increased all-cause mortality and LRE risks compared with non-SLD. Distinct zone-specific collagen patterns identified by AI analysis suggest unique fibrotic progression pathways in MetALD and ALD, supporting the need for tailored risk stratification and targeted management strategies.